All In Biotech

Drug Trial Radar · NCT06903338

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

124

Actual

Start

Mar 12, 2025

Primary completion

Sep 30, 2026

Study completion May 2031

Sponsor

Lead sponsor
Vir Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Mar 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.

Conditions

  • Viral Hepatitis

Interventions

  • TobevibartDrug

    Tobevibart administered by subcutaneous injection

  • ElebsiranDrug

    Elebsiran administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HDV RNA < Lower Limit of Quantification (LLOQ), Target Not Detected (TND) and alanine aminotransferase (ALT) normalization (ALT </= Upper Limit of Normal [ULN]) at Week 48 for Arm 1 vs at Week 12 for Arm 2Time frame: Up to 48 weeks
  2. Incidence of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 12Time frame: Up to 12 weeks

Locations

39 sites in 10 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Chandler, Arizona

  • Investigative Site

    Los Angeles, California

  • Investigative Site

    Redwood City, California

  • Investigative Site

    San Francisco, California

  • Investigative Site

    DeLand, Florida

  • Investigative Site

    Chicago, Illinois

  • Investigative Site

    Baltimore, Maryland

  • Investigative Site

    Hillsborough, New Jersey

  • Investigative Site

    New York, New York

  • Investigative Site

    New York, New York

  • Investigative Site

    New York, New York

  • Investigative Site

    Murray, Utah

  • Investigative Site

    Seattle, Washington

  • Investigative Site

    Montreal, Canada

  • Investigative Site

    Ottawa, Canada

  • Investigative Site

    Québec, Canada

  • Investigative Site

    Vancouver, Canada

  • Investigative Site

    Calgary, Alberta, Canada

  • Investigative Site

    Montreal, Quebec, Canada

  • Investigative Site

    Tbilisi, Georgia

  • Investigative Site

    Tbilisi, Georgia

  • Investigative Site

    Tbilisi, Georgia

  • Investigative Site

    Frankfurt, Germany

  • Investigative Site

    Hanover, Germany

  • Investigative Site

    Heidelberg, Germany

  • Investigative Site

    Chisinau, Moldova

  • Investigative Site

    Auckland, New Zealand

  • Investigative Site

    Karachi, Pakistan

  • Investigative Site

    Karachi, Pakistan

  • Investigative Site

    Lahore, Pakistan

  • Investigative Site

    Rawalpindi, Pakistan

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Kyiv, Ukraine

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    Manchester, United Kingdom

  • Investigative Site

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.